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Abstract
Background Data on clinical characteristics of patients
with inflammatory bowel disease (IBD)-related colorectal
cancer (CRC) are scarce and mainly originate from tertiary
referral centres. We studied patient and disease character-
istics of IBD-related CRC in a nationwide IBD cohort in
general hospitals. Main outcome parameters were time to
develop CRC, and factors associated with early CRC
development.
Methods All IBD patients diagnosed with CRC between
1 January 1990 and 1 July 2006 were identified using a
nationwide automated pathology database (PALGA).
Patient charts were assessed to confirm diagnosis and
collect clinical data. Early CRC was defined as CRC
diagnosed less than 8 years after IBD diagnosis. Statistical
analysis was performed using descriptive statistics,
independent t tests, binary logistic regression and Cox-
regression analysis.
Results Diagnosis of IBD-related CRC was confirmed in
251 patients (171 ulcerative colitis, 77 Crohn’s disease, 3
unclassified colitis), 161 males (64 %). Median time from
IBD diagnosis to CRC diagnosis was 12 years (IQR 4–20);
89 patients (35 %) developed early CRC. Type of IBD,
gender, concomitant PSC, pseudopolyps, extent of
inflammation, and medication use were not related to early
CRC (p [ 0.05). IBD diagnosis at older age (HR for
10 years older age 2.25; 95 % CI 1.92–2.63) was related to
early CRC. Twenty-three patients (12 %) had been inclu-
ded in a surveillance programme prior to CRC diagnosis.
Patients in the surveillance group had a significantly better
tumor stage (p = 0.004).
Conclusions We emphasize the problem of a high pro-
portion of IBD-associated CRCs developing before the
recommended start of surveillance. Therefore, we suggest
that older age at IBD onset could be an additional factor to
start surveillance in IBD patients.
Keywords Ulcerative colitis  Crohn’s disease 
Colorectal carcinoma  Risk factor
Introduction
Patients with chronic colitis due to ulcerative colitis (UC)
or Crohn’s disease (CD) carry an increased risk for colo-
rectal carcinoma (CRC) [1–3]. Previous studies have
mainly focused on the risk of acquiring inflammatory
bowel disease (IBD)-related CRC [4–9]. However, data on
clinical characteristics of IBD-related CRC cohorts,
including factors that lead to earlier development of CRC,
are scarce. Available studies have particularly focused on
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the relationship between age at onset of IBD and the
interval to CRC development [10–12]. However, the results
of these studies were inconsistent. Moreover, most studies
focussing on the interval between IBD and CRC are based
on specific tertiary cohorts including patients with a more
severe and complicated disease [11, 13, 14]. Data on both
patient and disease characteristics of patients with IBD-
related CRC from non-referral, community care centres are
lacking. It is therefore unknown whether the clinical
characteristics of these high-risk tertiary referrals differ
from the average IBD population in general hospitals.
Recently, the characteristics of patients with IBD-rela-
ted CRC from academic medical centres in the Netherlands
have been published [14]. Approximately 20 % of all IBD-
related CRCs in this cohort occurred in the first decade
after onset of IBD. The cohort of 149 patients with IBD-
related CRC mainly consisted of male UC patients with
extensive disease. This was a selected population with
results which may not reflect the total IBD population.
Furthermore, the study did not report any risk factors that
influence the interval between IBD and CRC in this aca-
demic population, and thus did not allow identification of
any subgroup of IBD patients which would require earlier
start of CRC surveillance.
Surveillance colonoscopies are an important strategy to
detect CRC at an early stage and thereby decrease CRC-
related morbidity and mortality [15, 16]. Currently, CRC
surveillance is recommended to start 8–10 years after the
onset of IBD in patients with extensive colitis and
15–20 years in those with left-sided colitis [17, 18]. More
recent guidelines recommend a first screening colonoscopy
8–10 years after disease onset in all IBD patients irre-
spective of disease extent [19, 20].
To implement evidence based surveillance strategies in
the total IBD population, characteristics of patients with
IBD-related CRC in general hospitals are needed. More-
over, parameters which lead to early development of CRC
in general hospitals need to be determined to identify
patients in need of earlier start of surveillance. For that
reason, our aim was to assess patient characteristics and
distinctive disease characteristics of IBD-related CRC in
patients from general hospitals in the Netherlands.
Materials and methods
Study population
Inflammatory bowel disease-related CRC patients in all 93
general hospitals in the Netherlands were identified using
the nationwide network and registry of histo- and cytopa-
thology (PALGA) [21]. The PALGA database contains all
pathology reports generated in the Netherlands from 1990
until present. These reports are all concluded with diag-
nostic terms in line with SNOMED terminology. Each
subject in the database has a unique identifier which allows
tracking of individual patients over time and throughout the
country. The following search criteria were used: (colon
AND/OR all primary carcinoma, colon AND/OR all car-
cinoma in situ, colon AND/OR all micro invasive tumors,
rectum AND/OR all primary carcinoma, rectum AND/OR
all carcinoma in situ, rectum AND/OR all micro invasive
tumors) AND (colitis AND/OR ulcerative colitis AND/OR
indeterminate colitis AND/OR idiopathic colitis AND/OR
Crohn’s disease).
Patients with histologically confirmed IBD and a syn-
chronous or metachronous CRC diagnosed between Janu-
ary 1, 1990 and July 1, 2006 were included. All IBD
patients diagnosed with colorectal cancer in a general
hospital were included, irrespective of where they were
treated afterwards. Patients who were initially treated and
diagnosed with cancer in an academic hospital and referred
to a general hospital after cancer diagnosis were excluded.
Clinical data were needed to confirm the diagnosis of IBD-
related CRC.
The study was approved by the Institutional Review
Board of the Erasmus MC Rotterdam, the Netherlands.
Data extraction
Further clinical data could be collected from 78 hospitals in
the Netherlands. The results from the search were verified
by the treating physicians in each hospital as well as by an
external expert. Clinical data were collected from the
patient charts, endoscopy reports and pathology reports.
The following data were collected: type of IBD, age,
gender, date of diagnosis of IBD and CRC, date of onset
symptoms attributable to IBD, duration of disease, disease
characteristics of IBD and CRC, history of colonic surgery,
presence of concomitant PSC, use of medication, and
surveillance details. Colonoscopies in the setting of dys-
plasia screening with multiple biopsies according to the
surveillance guidelines were counted as surveillance
colonoscopy [17, 18]. The complete medical history was
assessed, including prior colonoscopies and pathology
reports. Extent of disease was subdivided in five categories
based on type and extent of inflammation: left-sided UC,
extensive UC, limited CD, extensive CD or unclassified
colitis. Limited CD was defined as \50 % segmental CD
including those with terminal ileitis or ileocoecal inflam-
mation. Extensive CD was defined as [50 % segmental
CD. Severity of disease was graded as mild, moderate or
severe colitis based on both histological and endoscopic
features. Duration of medication-use during follow-up was
divided into four categories (0–25, 25–50, 50–75, [75 %
of duration of follow-up). Patients who appeared to have
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chronic inflammation due to any other cause but IBD, as
well as those in whom a diagnosis of CRC had not been
confirmed histologically, were excluded for further analysis.
‘‘Early CRC’’ was defined as CRC diagnosed within 8 years
after IBD diagnosis, irrespectively of disease extent.
Statistical analysis
Statistical analysis was performed using descriptive sta-
tistics, independent samples t tests, logistic regression, and
Cox-regression analysis. Follow-up time was defined as
time in years from start of diagnosis of IBD to diagnosis of
CRC. Patients who were simultaneously diagnosed with
IBD and CRC were excluded for all risk factor analyses for
the interval between IBD and CRC, since no comments can
be made on the interval between IBD and CRC in these
patients. Cox’s proportional hazards regression was used to
estimate univariable and multivariable hazard ratios to
analyse the effect of several risk factors for early devel-
opment of IBD-related CRC. Multivariate Cox regression
was performed stepwise-backward in which all variables
with a p value below 0.10 were included, provided they had
a plausible sign [22]. Univariate and multivariate logistic
regression was used to identify clinical characteristics
related to early CRC (\8 years after IBD diagnosis).
Groups were compared based on type of IBD, gender,
presence of concomitant PSC, pseudopolyps, rectal spar-
ing, severity and extent of inflammation, medication use
(ever used and duration of use), family history of CRC, and
histological signs of dysplasia prior to diagnosis of CRC. In
a sub-analysis we excluded patients C65 years old to
minimize the interference of sporadic CRC. Multivariate
logistic regression was performed stepwise-backward in
which all variables with a p value below 0.10 were inclu-
ded. Statistical analysis was performed with SPSS for
Windows software (version 15.0).
Results
PALGA search
Figure 1 represents a flow chart of the study population.
The initial search in the PALGA system revealed 3738
patients with a diagnosis compatible with IBD-associated
CRC (1941 males, 1797 females). After further analysis of
the pathology excerpts within the PALGA search, 3211
(86 %) patients were excluded for reasons of lack of his-
tological confirmation of IBD or CRC, colonic inflamma-
tion diagnosed years after the diagnosis of CRC, or colitis
due to other causes than IBD (e.g. diverticulitis).
Of the remaining 527 patients with a possible diagnosis
of IBD-related CRC, 59 patients (11 %) were [65 years
old. This group consisted of 37 males and 22 females, of
whom 51 patients had UC and 8 patients had CD.
In total, 527 patients were therefore eligible for
detailed chart review to confirm the diagnosis of IBD-
related CRC. Fifteen hospitals with a total of 38 (7 %)
patients were not willing to participate in the detailed
chart review.
In total, 489 patient charts, endoscopy and pathology
reports were assessed to confirm the diagnosis of IBD-
related CRC and collect clinical data. In 251 (51 %) out of
these 489 patients, the histological suspicion of IBD-rela-
ted CRC was confirmed based on additional clinical data,
including endoscopy and full histology reports.
Patient characteristics
Overall, in 251 patients the diagnosis of IBD-related CRC
was confirmed. Of these patients, 161 were male (64 %),
171 had UC (68 %), 77 had CD (31 %) and three patients
had unclassified colitis (2 %). Median age [interquartile
range (IQR)] at diagnosis of IBD was 40.1 years (IQR
24–58). Median age at CRC diagnosis was 56.4 years (IQR
44–65). Figure 2 shows the age at CRC diagnosis plotted
against the age at IBD diagnosis. Additional case charac-
teristics are listed in Table 1. In 170 (67 %) out of 251
cases start of IBD complaints was not retrievable from the
charts. Twenty-three patients (12 %) had been included in
a dysplasia surveillance program prior to CRC diagnosis
[data on surveillance were missing in 63 patients (25 %)].
On average, patients were included in a dysplasia surveil-
lance programme after 10 years of disease (IQR 7.5–24)
with an interval between each surveillance colonoscopy of
1 year (IQR 1–2.3).
Tumor characteristics
Forty-seven percent of tumors were located in the rectum
(n = 54) or sigmoid (n = 40). In 73 % of the cases
(n = 143) the tumor occurred in the colon segment affec-
ted by colitis. The location of chronic inflammation did not
influence the location of the tumor, p = 0.17. For UC
patients, those with left-sided UC had a RR of 1.5 (95 % CI
0.51–4.3, p = 0.5) to develop a tumor in the right part of
the colon compared with patients with pancolitis. More-
over, eight (35 %) out of 23 patients with a known left-
sided UC developed a tumor in the right part of the colon.
Eighty-four patients (43 %) had T3 tumors and 31
(16 %) metastases at time of CRC-diagnosis. Additional
tumor characteristics are listed in Table 2. The distribution
in tumor sites differed between UC and CD patients. For 59
(24 %) patients (50 UC and 9 CD), the exact tumor loca-
tion could not be retrieved. In the remainder, 78 out of 121
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UC patients (64 %) developed a tumor in the left part of the
colon, compared with 33 out of 68 CD patients (49 %),
p = 0.022. Patients who were included in a surveillance
programme had a significantly better AJCC tumor stage
(p = 0.004). Twelve (52 %) out of 23 patients (AJCC
tumor stage unknown in one patient) in the surveillance
group had a stage I tumor compared with 31 (19 %) out of
165 patients in the non-surveillance group (AJCC tumor
stage unknown in eight patients). In addition, surveillance
was associated with a better T-stage (p = 0.002). Only five
patients in the surveillance group (22 %) had a T3 tumor at
time of diagnosis compared to 67 patients (41 %) in the
non-surveillance group. Surveillance did not influence the
metastasis at time of diagnosis of during follow-up
(p = 0.9).
CRC development within 8 years after IBD diagnosis
In seven (2.8 %) patients the exact date at which they had
been diagnosed with IBD was unknown. These patients
were therefore excluded for the following analyses with
regard to the interval between onset of IBD and CRC
diagnosis. The time interval between IBD and CRC with
entry point confirmed diagnosis of IBD was, on average,
12 years (IQR 4–20). Overall, 89 patients (35 %) devel-
oped CRC within 8 years after IBD diagnosis, and 115
Assessed for eligibility by initial
PALGA search
(n= 3738)
3211 (86%) patients were 
excluded for not meeting 
inclusion criteria
527 patients eligible 
for chart review
489 patient charts, 
endoscopy-, and 
pathology reports were 
assessed
238 patients were 
excluded because IBD 
or CRC could not be 
confirmed
251 patients had a
confirmed diagnosis of 
IBD and CRC
15 hospitals refused to 
participate (n=38)
Fig. 1 Flow chart study
population
Fig. 2 Age at IBD diagnosis versus age at CRC diagnosis. The age at
IBD diagnosis is plotted against the age at which patients are
diagnosed with CRC. This figure demonstrates that age at onset of
IBD is not related to the age at which patients develop CRC
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Table 1 Patient characteristics
N
All cases (%)
N
Simultaneously diagnosed
IBD ? CRC excluded (%)
Total UC CD Total UC CD
No. of patients 251 171 77 216 150 64
Disease
Ulcerative colitis 171 (68) 171 – 150 (69) 150 –
Crohn’s disease 77 (31) – 77 64 (30) – 64
Unclassified colitis 3 (2) – – 2 (1) – –
Gender
Male 161 (64) 114 (67) 45 (58) 138 (64) 103 (69) 34 (53)
Female 90 (36) 57 (33) 32 (42) 78 (36) 47 (31) 30 (47)
Median interval between IBD
and CRC (IQR)
11.7 years
(IQR 4–21)
11 years
(IQR 4–20)
13.6 years
(IQR 4–25)
14.0 years
(IQR 7–23)
13.2 years
(IQR 6–22)
17.2 years
(IQR 9–26)
Median age at diagnosis IBD (IQR) 41.1 years
(IQR 24–58)
45.7 years
(IQR 26–64)
32.6 years
(IQR 23–51)
35 years
(IQR 23–56)
43 years
(IQR 24–60)
28.8 years
(IQR 21–42)
Median age at diagnosis CRC (IQR) 56.4 years
(IQR 44–65)
58.4 years
(IQR 46–69)
50.7 years
(IQR 41–61)
56.4 years
(IQR (43–65)
58.9 years
(IQR 47–70)
50 years
(IQR 40–60)
Disease extent
Leftsided colitis (UC) 23 (9) 22 (13) – 17 (8) 17 (11) –
Pancolitis (UC) 57 (23) 79 (46) – 54 (25) 54 (36) –
\50 % segmental colitis (limited CD) 23 (9) – 20 (26) 15 (7) – 15 (23)
[50 % segmental colitis (extensive CD) 38 (15) – 34 (44) 35 (16) – 34 (53)
Extensive unclassified colitis 2 (1) – – 1 (0) – –
Unknown 108 (40) 70 (410) 23 (30) 94 (44) 79 (53) 15 (23)
Severity of disease
Mild 20 (8) 15 (9) 4 (5) 15 (7) 11 (7) 4 (6)
Moderate 62 (25) 38 (22) 23 (30) 56 (26) 35 (23) 20 (31)
Severe 73 (29) 48 (29) 25 (32) 65 (30) 43 (29) 22 (34)
Unknown 96 (38) 70 (41) 25 (32) 80 (37) 61 (41) 18 (28)
Pseudopolyps
Yes 72 (29) 51 (30) 29 (38) 71 (33) 45 (30) 25 (39)
No 81 (32) 45 (26) 25 (32) 64 (30) 41 (27) 22 (34)
Unknown 98 (40) 75 (44) 23 (30) 81 (38) 64 (43) 17 (27)
Concomitant PSC
Yes 19 (8) 14 (8) 4 (52) 18 (8) 13 (9) 4 (6)
No 162 (65) 101 (59) 59 (77) 140 (68) 90 (60) 49 (77)
Unknown 70 (28) 56 (33) 14 (18) 58 (27) 47 (31) 11 (17)
Positive family history CRC
Negative 82 (33) 53 (31) 29 (38) 68 (33) 44 (29) 23 (36)
Positive 1st degree 9 (4) 5 (3) 5 (6) 7 (3) 5 (3) 2 (3)
Positive 2nd degree 4 (2) 1 (1) 1 (1) 4 (2) 3 (2) 1 (2)
Unknown 156 (62) 112 (63) 42 (54) 137 (63) 98 (65) 38 (59)
Ongoing active inflammation
No 125 (50) 85 (50) 39 (51) 115 (53) 79 (53) 35 (55)
Yes 38 (15) 23 (13) 14 (18) 28 (13) 17 (11) 11 (17)
Unknown 88 (35) 63 (37) 24 (31) 73 (34) 54 (36) 18 (28)
Colon surgery prior to onset IBD
No 165 (66) 104 (61) 58 (75) 143 (66) 93 (62) 48 (75)
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patients (47 %) experienced CRC within the first decade
after IBD diagnosis. In the group that developed CRC
within 8 years after diagnosis of IBD, the median age at
IBD diagnosis was 58.8 years (IQR 48–69), compared with
a median age of 28.4 years (IQR 22–45) in those who
developed CRC [ 8 years of IBD, p \ 0.001. The age at
CRC diagnosis was on average 61.6 years (IQR 49–73) in
those who developed CRC \ 8 years of disease, compared
with a median age of 53.5 (IQR 43–62) in those who
developed CRC [ 8 years of disease (p = 0.08). Figure 3
shows that the median age at CRC diagnosis is independent
of the duration of IBD. Table 3 presents the clinical
characteristics of those who developed CRC within
8 years. Excluding patients[65 years old did not influence
the results with regard to early development of CRC.
Simultaneous diagnosis of IBD and CRC
Thirty-five patients (14 %) were diagnosed with IBD and
CRC simultaneously of within 6 months after IBD diagnosis
(21 had UC, 13 had CD, and one patient had unclassified
colitis). Of these 13 CD patients one had a tumor in the rectum,
one in the sigmoid, two in colon transversum, four in the
ascending colon, four in the caecum (data missing in one
patient). For the UC patients, in eight patients the tumor was
located in the rectum, in five patients in the sigmoid, two in the
splenic flexure, two in the ascending colon and one in the
caecum. Patient characteristics of this group are listed in
Table 1 and tumor characteristics in Table 2. All these
patients were [37 years old at time of IBD diagnosis. One
patient reported having had IBD-related complaints for
23 years from the age of 19 onwards (data on start of symp-
toms missing in 21 patients). Of the CD patients with a
simultaneous diagnosis of IBD and CRC, seven had limited
CD (78 %) against two patients with extensive CD (22 %)
(p = 0.022). In four patients data on the extent of CD was
missing. Of the 36 UC patient diagnosed simultaneously with
IBD and CRC, in six patients the extent of IBD was known:
three had left-sided colitis and three had pancolitis (p = 0.35).
Factors influencing the time interval between onset
of IBD and CRC
As stated in the methods section, patients with simulta-
neous diagnosis of IBD and CRC were excluded for the
following risk factor analysis with regard to the time
interval between IBD and CRC.
Univariable cox regression analysis showed that type of
IBD, gender, presence of concomitant PSC, pseudopolyps,
rectal sparing (UC patients), severity and extension of
inflammation, a positive family history of CRC, presence
of dysplasia prior to CRC diagnosis, or ongoing active
inflammation of IBD, without any remission during follow-
up, were not significantly associated with early develop-
ment of CRC (all p [ 0.05, Table 4). Diagnosis of IBD at
older age was associated with early development of CRC
(HR for 10 years older age 2.25; 95 % CI 1.92–2.63).
Excluding patients [65 years old did not influence the
factors associated with early development of CRC.
The extent of inflammation did not correspond with the
time to development of CRC (p = 0.53). However,
patients with pancolitis had more often been treated with
5-ASA (49/50 = 98 %) than patients with left-sided colitis
(15/20 = 75 %), p = 0.06. In addition, UC patients with
left-sided colitis were more often diagnosed with IBD at an
older age (median age 43.4 years; IQR 27–55) compared
with UC patients suffering from pancolitis (median age
27.9 years; IQR 21–44), p = 0.02.
For all medications (5-ASA, corticosteroids, azathio-
prine, methotrexate, anti-TNF, ursodeoxycholic acid, folic
Table 1 continued
N
All cases (%)
N
Simultaneously diagnosed
IBD ? CRC excluded (%)
Total UC CD Total UC CD
Yes 7 (3) 3 (2) 4 (5) 7 (3) 3 (2) 4 (6)
Unknown 79 (31) 64 (37) 15 (19) 66 (31) 54 (36) 12 (19)
Rectal sparing (UC ? unclassified)
Negative 73 (43) 70 (41) – 62 (41) 60 (40) –
Positive 3 (2) 3 (2) – 3 (2) 3 (2) –
Unknown 95 (56) 98 (570) – 87 (57) 87 (58) –
Dysplasia found prior to CRC diagnosis
No 164 (65) 99 (58) 63 (82) 139 (64) 87 (58) 51 (80)
Yes 30 (12) 23 (13) 6 (8) 28 (13) 21 (14) 6 (9)
Unknown 57 (23) 49 (29) 8 (10) 49 (23) 42 (28) 7 (10)
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acid and ferrofumerate) no significant correlations with the
time to develop CRC were found (Table 5). Duration of
medication use did not significantly influence the time to
CRC diagnosis for any type of drug. Starting 5-ASA
directly at the time of IBD diagnosis did not influence the
interval between IBD and CRC (p = 0.24).
Multivariate analysis of factors related to the interval
between IBD and CRC
Age at onset IBD, rectal sparing (UC patients), colorectal
surgery prior to onset IBD, and ongoing active inflamma-
tion during follow-up were assessed in a multivariate
Table 2 Tumor characteristics
N
All cases (%)
N
Excluding simultaneously diagnosed IBD ? CRC (%)
Total UC CD Total UC CD
No. of patients 251 171 77 216 150 64
CRC location
Rectum 54 (22) 35 (20) 18 (23) 45 (21) 28 (19) 17 (27)
Sigmoid 40 (16) 29 (17) 10 (13) 36 (17) 26 (17) 9 (14)
Descending colon 9 (4) 8 (5) 1 (1) 9 (4) 8 (5) 1 (2)
Splenic flexure 10 (4) 6 (4) 4 (5) 8 (4) 4 (3) 4 (6)
Transverse colon 17 (7) 8 (5) 9 (12) 15 (7) 8 (5) 7 (11)
Hepatic flexure 6 (2) 3 (2) 3 (4) 6 (3) 3 (2) 3 (5)
Ascending colon 17 (7) 10 (6) 7 (9) 12 (6) 8 (5) 4 (6)
Caecum 27 (11) 14 (8) 12 (16) 22 (10) 13 (9) 8 (13)
Double tumors 10 (4) 7 (4) 3 (4) 10 (5) 7 (5) 3 (5)
Unknown 61 (24) 51 (30) 10 (13) 53 (5) 45 (30) 8 (13)
T-stage
Tis 10 (4) 8 (5) 3 (4) 8 (4) 5 (3) 3 (5)
T1 25 (10) 19 (11) 5 (6) 20 (9) 16 (11) 4 (6)
T2 36 (14) 25 (15) 11 (14) 31 (14) 23 (15) 8 (13)
T3 84 (33) 54 (32) 30 (39) 72 (33) 46 (31) 25 (39)
T4 32 (13) 14 (8) 17 (22) 29 (13) 13 (9) 15 (23)
Tx 64 (25) 51 (30) 11 (14) 56 (26) 47 (31) 9 (14)
N stage
N0 102 (41) 63 (37) 38 (50) 85 (39) 53 (35) 32 (50)
N1 62 (25) 39 (23) 22 (29) 55 (25) 36 (24) 18 (28)
N2 20 (8) 13 (8) 6 (8) 18 (8) 12 (8) 5 (8)
Nx 65 (26) 56 (33) 11 (14) 58 (27) 49 (33) 6 (15)
M stage
M0 155 (62) 100 (58) 53 (69) 129 (60) 85 (57) 43 (67)
M1 32 (13) 20 (11) 12 (16) 32 (15) 19 (13) 12 (19)
Mx 64 (26) 51 (30) 12 (16) 55 (25) 46 (31) 9 (15)
AJCC stage (6th edition)
I 45 (18) (18) 13 (17) 37 (17) 27 (18) 10 (16)
IIa 32 (13) 20 (12) 12 (16) 27 (13) 17 (11) 10 (16)
IIb 6 (2) 3 (2) 3 (4) 4 (2) 2 (1) 2 (3)
IIIa 13 (5) 12 (7) 1 (1) 11 (5) 11 (7) –
IIIb 35 (14) 18 (11) 16 (21) 31 (14) 16 (11) 14 (22)
IIIc 10 (4) 8 (5) 2 (3) 8 (4) 7 (47) 1 (2)
IV 34 (14) 19 (11) 14 (18) 33 (15) 19 (13) 13 (21)
Unknown 76 (30) 60 (35) 16 (21) 65 (30) 51 (34) 14 (22)
Metastasis spread during follow-up 59 (24) 32 (19) 25 (32) 54 (25) 31 (21) 21 (14)
CRC in previous inflamed areas 143 (57) 89 (52) 52 (68) 129 (60) 81 (54) 47 (73)
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Cox-regression analysis. After correcting for possible con-
founders, age at onset of IBD (HR 10 years older age 2.29;
95 % CI 1.92–2.74, p \ 0.001) and ongoing active inflam-
mation during follow-up (HR 1.5; 95 % CI 1.0–2.29,
p = 0.04) were significantly correlated with a shorter interval
between IBD and CRC. Figure 4 demonstrates the relation-
ship between age at IBD diagnosis and time to develop CRC.
Discussion
We present a large nationwide general hospital study on the
characteristics of IBD-related CRC. In this cohort we
demonstrate early occurrence of IBD-related CRC and we
show that a high proportion of IBD-associated CRCs
develop before the recommended start of surveillance.
Moreover, the patients who were included in a surveillance
program had significantly better tumor characteristics. We
identified a subgroup of patients in need of earlier start of
surveillance.
A large number of patients (35 %) developed CRC in
less than 8 years after diagnosis of IBD, which is before the
recommended start of surveillance. Our results underline
the results of two recently published academic cohorts, in
which approximately 20 % of IBD-related tumors occurred
within 10 years after IBD diagnosis [13, 14]. Probably,
start of IBD-related symptoms instead of interval since
diagnosis better estimates the years at risk for developing
CRC; however, the actual date of onset of symptoms that
were in fact related to IBD are difficult to retrieve and may
lead to recall bias. In our cohort, in 170 out of 251 cases
(68 %) data were lacking concerning the actual onset of
IBD-related symptoms prior to the baseline diagnosis.
The guidelines for surveillance are currently being
altered. The classic guidelines recommended to start
bi-annual colonoscopy surveillance after 8–10 years for
extensive colitis and 15–20 years for left-sided disease
(from onset of symptoms) [17]. However, more recent
guidelines suggest to perform a screening colonoscopy
after 8–10 years of disease in all IBD patients, to assess the
true microscopic extent of inflammation [18, 20]. Our data
are in line with these adjustments, as location of IBD did
not influence the time to develop CRC in our cohort.
However, more than one third of all cases occur before
this newly recommended screening schedule. Diagnosis of
IBD at older age is significantly related to early develop-
ment of IBD-related CRC in our cohort. This has also been
demonstrated in previous studies [10, 13]. In large contrast
to the older age at which patients with early CRC were
diagnosed with IBD, the median age at time of CRC
diagnosis was equal compared with those who developed
CRC [8 years after IBD diagnosis. This suggests that age
at onset of IBD, and not duration of disease is a leading
factor for early development of CRC in IBD patients. This
could among others be explained by the fact that in UC
patients colonocyte telomeres shorten with age almost
twice as rapidly as in normal controls [23]. Telemore-
shortening is associated with the development of cancer
and colonocytes of UC patients show premature shortening
of telomeres, which might in part explain the increased and
earlier risk of cancer in this disease. Future research is
needed to support this hypothesis. Another explanation
might be that patients with late onset of IBD, similar to the
general population, accumulate malignant risk factors until
the onset of IBD [24].
Even though almost half of the patients with CRC had
extensive colitis, the majority of IBD-related tumors were
located in the left colon and already advanced tumor stages
were found at time of diagnosis. More advanced tumors
(AJCC stage III tumor) were found in our non-academic
cohort (30 %) compared with the Dutch academic cohort
(20 %). This might be explained by the fact that only 12 %
of our patients were included in a dysplasia surveillance
programme before development of CRC, against a slightly
higher percentage (15 %) in the academic cohort. Sur-
veillance colonoscopies are not yet common practice in
general hospitals in the Netherlands and most gastroente-
rologists in the Netherlands do not adhere to surveillance
guidelines [25]. This low adherence to colonoscopy sur-
veillance in IBD patients reflects clinical practice in gen-
eral hospitals with a presumed perception of low CRC risks
in these populations. This perception has to change, as our
findings support the inclusion of patients in surveillance
strategies and show that surveillance was associated with
earlier detection and thus improved tumor stage. Our
findings are supported by previous studies, which also
Fig. 3 Age at CRC diagnosis is independent of duration of IBD. The
duration of IBD is plotted against the median age at which patients
developed CRC. This figure demonstrates that age at CRC-diagnosis
is independent of duration of IBD
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Table 3 One third of patients developed CRC within 8 years after IBD diagnosis: clinical characteristics of early CRC
Early
CRC \ 8 years
(%)
p value
(univariate
logistic regression)
RR (95 % CI)
(multivariate
logistic regression)
p value
(multivariate
logistic regression)
Total no. of patients with early CRC 89 (35)
Type of IBD p = 0.3 –
Ulcerative colitis 64 (37)
Crohn’s disease 23 (30)
Unclassified colitis 2 (67)
Gender p = 0.8 –
Male 58 (36)
Female 31 (34)
Age at diagnosis IBD (years) p < 0.001 HR 10 years older
age: 4.5 (2.7–7.2)
p \ 0.001
\20 1 (3)
20–30 3 (6)
30–40 9 (28)
40–50 14 (40)
50–60 19 (56)
[60 42 (75)
Disease extent (years) p = 0.005 p = 0.07
Left-sided colitis (UC) 11 (48)
Pancolitis (UC) 11 (20)
\50 % segmental colitis (limited CD) 12 (52)
[50 % segmental colitis (extensive CD) 5 (14)
Extensive unclassified colitis 2 (100)
Severity of disease p = 0.01 p = 0.25
Mild 13 (62)
Moderate 17 (27)
Severe 18 (25)
Pseudopolyps p = 0.06 –
No 30 (38)
Yes 17 (24)
Concomitant PSC p = 0.7 –
No 49 (31)
Yes 5 (26)
Positive family history CRC p = 0.98 –
Negative 30 (37)
Positive 1st degree 3 (3)
2nd degree –
Ongoing active inflammation p = 0.01 5.2 (1.6–16.3) p = 0.018
No 30 (24)
Yes 18 (47)
Colon surgery prior to onset IBD p = 0.11 –
No 45 (28)
Yes 4 (57)
Rectal sparing (UC) p = 0.25 –
Negative 23 (32)
Positive 2 (67)
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Table 4 Parameters
influencing a short interval
between IBD and CRC
development (univariate cox
regression)
a 36 patients with simultaneous
IBD and CRC were excluded
for this risk factor analysis
Median time
to CRC-diagnosis
in years (IQR)
Hazard ratio
(95 % CI)
p value
No. of patients 215 (%)a
Type of IBD p = 0.3
Ulcerative colitis 13.0 (6–21) 1.0
Crohn’s disease 17 (9.3–26.8) 0.59 (0.15–2.38)
Unclassified colitis 11 (5–17) 0.48 (0.12–2.0)
Gender p = 0.48
Female 14 (6.5–22.0) 1.0
Male 14 (7–24) 1.1 (0.83–1.47)
Age at diagnosis IBD (years) p \ 0.001
\20 24.5 (18.8–34.9) 1.0
20–30 19.8 (15.4–30.7) 1.7 (1.1–2.7)
30–40 16 (8.3–21.6) 3.9 (2.3–6.7)
40–50 12.1 (4.5–14.9) 7.0 (4.0–12.2)
50–60 7.2 (4.2–8.4) 21.0 (10.3–42.7)
60–65 3.5 (0.9–4.8) 59.8 (22.1–161.7)
Disease extent (years) p = 0.3
Left-sided colitis (UC) 11.5 (2.5–22.8) 1.0
Pancolitis (UC) 17.7 (10.9–24.2) 0.66 (0.39–1.12)
\50 % segmental colitis (limited CD) 12.7 (4.5–29.7) 0.73 (0.38–1.41)
[50 % segmental colitis (extensive CD) 18.0 (13.4–25.8) 0.65 (0.37–1.13)
Extensive unclassified colitis 4.3 (4.3–4.3) 5.41 (0.69–42.5)
Severity of disease p = 0.26
Mild 9.0 (2.8–22.7) 1.0
Moderate 18.9 (9.5–24.9) 0.62 (0.36–1.01)
Severe 16.3 (8.5–22.2) 0.72 (0.42–1.24)
Pseudopolyps p = 0.7
No 17.7 (6.1–26) 1.0
Yes 16.0 (8–23.2) 1.07 (0.76–1.5)
Concomitant PSC p = 0.5
No 16.6 (8.1–25.1) 1.0
Yes 18.3 (8.2–23.9) 1.19 (0.72–1.95)
Positive family history CRC p = 0.19
Negative 16.1 (7.5–23.2) 1.0
Positive 1st degree 15.0 (10–20.3) 1.23 (0.56–2.7)
2nd degree 32.5 (20.2–37.3) 0.43 (0.16–1.2)
Ongoing active inflammation p = 0.11
No 17.4 (9.3–24.7) 1.0
Yes 14.5 (3.8–23.2) 1.39 (0.93–2.07)
Colon surgery prior to onset IBD p = 0.08
No 17.5 (9.7–24.7) 1.0
Yes 7.3 (2.1–23.2) 1.97 (0.92–4.23)
Rectal sparing (UC) p = 0.08
Negative 13.7 (7.5–20.8) 1.0
Positive 7.7 (4.8–12.4) 2.91 (0.88–9.65)
Dysplasia found prior to CRC diagnosis p = 0.23
No 15.4 (8.4–24.1) 1.0
Yes 17.6 (5.4–24.6) 0.83 (0.61–1.13)
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demonstrated that surveillance colonoscopies may detect
CRC at an earlier stage and improve prognosis [15, 16].
Only recently, nationwide guidelines were launched for
surveillance colonoscopies [26]. During our study period,
surveillance was not regularly performed in the Nether-
lands. This underscores the need for an increased surveil-
lance programme with an earlier start in the high risk
group. However, more data are needed to establish proper
surveillance methods in Crohn’s disease. For UC it has
been estimated that 33 biopsy specimens are required to
give 90 % confidence to detect dysplasia if it is indeed
present [27]. However, the focal nature of inflammation in
CD, the possibility of strictures and the prevalence of
segmental resection means that surveillance practice in UC
cannot be transferred directly to CD. The use of targeted
biopsies, aimed at lesions identified by chromoendoscopy
or endomicroscopy, has changed the policy of taking
biopsies in UC and this policy should also be considered in
patients with CD. However, more data are needed to
establish a proper surveillance method in Crohn’s disease.
Strikingly, in 36 out of 251 patients (14 %), IBD and
CRC were diagnosed simultaneously. All these patients
were [37 years old at time of IBD diagnosis, which sup-
ports our notion that age at onset of IBD is probably a
leading factor for early CRC. Most patients (15/21 patients,
data missing in 15 cases) already had symptoms
Table 5 Medication use does
not protect against early CRC
a In 56 cases data on
medication use was not
retrievable
Cases Median time to diagnosis
CRC in years (IQR)
Hazard Ratio
(95 % CI)
p value
No. of patients 159 (%)a –
5-ASA p = 0.69
Yes 137 (86) 17.3 (9.8–24.2) 0.91 (0.58–1.44)
No 22 (14) 16.4 (3.3–28.1) 1.0
Thiopurines p = 0.97
Yes 36 (23) 17.4 (13.1–24.6) 1.01 (0.69–1.45)
No 123 (77) 16.9 (8–24.5) 1.0
Corticosteroids p = 0.24
Yes 102 (64) 17.6 (10.9–24.5) 0.82 (0.59–1.14)
No 57 (36) 15.9 (5–24.6) 1.0
MTX p = 0.47
Yes 2 (1) 14.7 (11.6–17.8) 1.68 (0.41–6.83)
No 157 (99) 17.3 (8.8–24.5) 1.0
Anti-TNF p = 0.34
Yes 4 (3) 17.2 (8.4–17.8) 1.63 (0.6–4.46)
No 155 (97) 17.2 (9–24.5) 1.0
Ascal p = 0.34
Yes 5 (3) 17.2 (5.3–34.5) 0.65 (0.26–1.6)
No 154 (97) 15.4 (8.9–24.5) 1.0
NSAIDS p = 0.11
Yes 7 (4) 14.7 (0.9–20.6) 1.85 (0.86–3.98)
No 152 (96) 15.7 (9.1–24.6) 1.0
Folic acid p = 0.71
Yes 16 (10) 14.6 (10.6–27.4) 1.11 (0.66–1.86)
No 143 (90) 17.4 (8–24.5) 1.0
Calcium p = 0.36
Yes 10 (6) 16.5 (11.2.21.4) 1.34 (0.7–2.56)
No 149 (94) 17.3 (8.8–24.5) 1.0
Ursodeoxy acid p = 0.57
Yes 13 (8) 23 (17.6–24.1) 0.85 (0.48–1.5)
No 146 (92) 16.3 (8.5–24.5) 1.0
Ferrofumerate p = 0.25
Yes 47 (30) 17.8 (11.8–26.2) 0.82 (0.58–1.16)
No 112 (70) 16.5 (8–24.4) 1.0
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attributable to IBD before diagnosis. In the Dutch academic
cohort 7 % of patients were diagnosed with IBD and CRC
simultaneously [14]. However, this academic cohort also
yielded a higher surveillance rate and they found less
advanced tumors in their cohort. This might be explained
by a difference in clinical practice between general hos-
pitals and academic hospitals. This emphasizes the clinical
relevance of our study to distinguish between several
patients group, both in a academic setting as in the general
population.
Inflammatory bowel disease patients with concomitant
PSC and a positive family history of CRC are at increased
risk for developing CRC [4, 7, 28–30]. However, we could
not confirm that these factors also lead to earlier develop-
ment of CRC, which is also endorsed by results from
previous studies [13, 31, 32]. These results suggest that,
although PSC and a familial predisposal of CRC are risk
factors for acquiring CRC, they are not a driving force for
earlier development of IBD-related CRC. It therefore
remains a discussion whether we should perform surveil-
lance colonoscopies more frequently in these patients.
However, our results could be biased due to the relatively
small number of patients with PSC in our non-academic
cohort. Moreover, the number of patients with a positive
family history of CRC might be under-recorded in a ret-
rospective study. Therefore caution is needed in interpret-
ing these results.
Use of medication and duration of medication use did
not influence the interval between IBD and CRC in our
cohort. Previous studies have demonstrated 5-ASA use to
be protective for acquiring CRC [5, 33–35]. However, we
could not confirm this in our cohort. This could be influ-
enced by the retrospective data collection, in which
duration of medication use was subdivided in four different
periods and therefore not assessed as a continuous factor.
Furthermore, medication use could have been prone to
information bias due to the retrospective study design.
A recently published study from Sweden demonstrated
that male patients have an overall 60 % higher rate of CRC
than female patients [36]. However, there was no effect of
sex on the RR within 10 years after IBD-diagnosis.
Although we did not focus on gender differences, we can
conclude that in our cohort also more male patients
developed IBD-related CRC during our study-period of
15 years. However, we did not correct this for possible
confounders as age and type of IBD. Although male
patients were in the majority in our cohort, gender did not
influence early development of CRC in our cohort.
Although the Swedish study did not assess the time interval
between IBD onset and CRC development, they could not
identify a RR difference within 10 years of IBD, which
supports our results.
In our study, eight out of 23 patients with a known left-
sided UC developed a tumor in the right part of the colon.
All patients had a well established IBD. However, it has
been demonstrated that colonoscopy frequently underesti-
mates the extent of colitis activity, as shown by histological
evidence of colitis in macroscopically normal areas of the
mucosa [37–40]. Therefore, the ECCO-guidelines recom-
mend to perform a colonoscopy with histological biopsies
in every IBD patient after 8 years of disease to establish the
true extent of disease, even in those with only limited
colitis [41]. However, in our study-period this was not yet
common practice. This could explain why in eight out of
23 patients with a left-sided UC, the tumor was developed
in the right part of the colon.
In our cohort, only 13 % of the cases were identified
with dysplasia. However, our study was not primary
designed to identify dysplasia. In order to determine how
many cases of true dysplasia were identified during our
study-period, we have searched the PALGA database for
patients with true dysplasia in the 38 largest non-academic
hospitals of the Netherlands. We identified 4436 patients
suggestive for dysplasia and a possible diagnosis of IBD in
their medical history. However, as in our study, many
patients will be excluded after manual review of the search
and reviewing clinical data in patient charts. Unfortunately,
it was not feasible to verify all diagnoses in the hospital
charts of this large group of patients all over the country.
Moreover, a recent study has demonstrated that histological
review of histological slides by a panel of experts reduced
the total number of flat low-grade dysplasia patients with
approximately 75 % [42].
In 2005, the Crude Incidence rate for CRC in the
Netherlands was 66.73 per 100,000 persons [43]. This
comprises all kinds of CRC, including IBD-related CRC.
Fig. 4 Age at IBD diagnosis is related to the time to develop CRC.
This figure shows the time to develop CRC against the age at which
patients were diagnosed with IBD. This shows that age at IBD
diagnosis is related to the time to develop CRC
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Earlier, we have demonstrated that the population rate for
IBD-related CRC between 1990 and 2005 was approxi-
mately 0.05 % per year [44]. In a sub-analysis we excluded
patients [65 years old to minimize possible interference
with sporadic CRC. However, excluding this subgroup of
patients did not influence our results with regard to early
development of CRC. Moreover, all of our patients had a
well-established IBD. Therefore we believe we maximally
reduced the interference with sporadic CRC in our cohort.
Although we are aware of the limitations of a retro-
spective study design, this design was carefully chosen to
fit our main aim to study the overall epidemiology of IBD-
related CRC. Unfortunately not all data could be retro-
spectively recovered from the clinical charts, which is
attributed to the retrospective study design. Because of the
considerable time-interval to development of CRC in IBD
and the low frequency of IBD-related CRC in general
hospitals, conducting a prospective study would not be
feasible. Using a retrospective analysis, we were able to
perform a large nationwide survey with a follow-up time of
15 years.
In conclusion, our results emphasize the problem of a
high proportion of IBD-associated CRCs developing before
the recommended start of surveillance. Secondly, we
demonstrate that surveillance is associated with a better
tumor stage. This underlines the need to identify a sub-
group of patients that require earlier start of surveillance.
Based on our results, we suggest that older age at onset of
IBD could be an additional factor to start surveillance in
IBD patients. Accordingly, we would recommend earlier
start of surveillance and an immediate start at time of IBD
diagnosis for patients diagnosed with IBD above the age of
45 years. Moreover, better registration of start of symp-
toms is needed. Adapting the surveillance guidelines and
identifying patients in need of earlier start of surveillance
will detect CRC at an earlier stage and may therewith
improve prognosis.
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